| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 36.9 | 58.8 |
| Profit before tax | -14.2 | 1.2 |
| Net income | -14.4 | 0.5 |
| EPS (diluted, $ a share) | $-0.05 | $0.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -37.2% |
|---|---|
| Operating margin | -31.1% |
10-Q filed with the SEC, NASDAQ: AKBA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Akebia Therapeutics, Inc.: key numbers
- Share price
- $0.4004Close, Nov 17
- Market cap
- $111M
- Shares outstanding
- 277.66MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Akebia Therapeutics, Inc.
All →Akebia Therapeutics $140M Debt Financing with Symbiotic Capital Opportunities Holding, L.P.
Akebia Therapeutics entered into a $140 million senior secured term loan facility with Symbiotic Capital, consisting of a $60 million initial tranche and $80 million in discretionary tranches. The company used the initial proceeds to repay its existing $55 million debt facility with BlackRock (Kreos). The new facility features a 60-month interest-only period with a maturity date of November 12, 2031.
- Value
- $140M
- Counterparty
- Symbiotic Capital Opportunities Holding, L.P.
- Term
- 5 years
Akebia Therapeutics Financial Results
Akebia Therapeutics reported Q3 2026 financial results, highlighted by a 140% year-over-year increase in patients on Vafseo to approximately 11,500. The company reported Vafseo net product revenues of $14.8 million and maintained a strong cash position of $159.3 million as it prepares for expanded market access in 2027.
- Term
- Q3 2026
“Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continuing to increase the number of patients on therapy.”
John P. Butler, Chief Executive Officer of Akebia
“We believe this compelling data has the potential to drive Vafseo to be standard of care. We continue to work to strengthen our market position as we enter 2027 when we believe Vafseo access will expand beyond the Transitional Drug Add-on Payment Adjustment (TDAPA)-only patients to nearly all clinically eligible patients.”
John P. Butler, Chief Executive Officer of Akebia
Akebia Therapeutics Nasdaq/NYSE Compliance Notice
Akebia Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 19, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least 10 consecutive business days. Akebia is evaluating options to cure the deficiency, including a potential reverse stock split.
- Counterparty
- Nasdaq
- Term
- 180 days
Akebia Therapeutics Leadership Change
Nicholas Grund, Senior Vice President and Chief Commercial Officer, notified Akebia Therapeutics of his resignation effective November 6, 2026, for personal reasons. Following his departure, Mr. Grund will provide consulting and advisory services to the company through April 30, 2027, under a newly established consulting agreement.
- Term
- through April 30, 2027